Literature DB >> 338514

Circulating immune complexes in patients with malignant lymphomas and solid tumors.

H E Heier, N Carpentier, G Lange, P H Lambert, T Godal.   

Abstract

Sera from 50 patients with Hodgkin's disease, 78 patients with non-Hodgkin non-leukemic malignant lymphomas, and 75 patients with different types of solid malignant tumors were investigated for the presence of immune complexes using the (125I) C1q-binding test. All patients were untreated. An increased serum C1q-binding activity was found in 22% of the patients with Hodgkin's disease, 35.9% of the non-Hodgkin lymphoma patients and in 37.3% of the patients with solid tumors. The C1q-binding material detected in the patients' sera had properties similar to those of immune complexes. On sucrose density gradient it sedimented as a 10-30 s material. It contained IgG which were dissociated under acid conditions. Passage through anti-IgG immunoabsorbent removed its C1q-binding properties. A prevalent association was found between the presence of serum immune complexes and disseminated disease stages in all the patient groups included. A similar association was found between the presence of serum immune complexes and general symptoms among the malignant lymphoma patients. The nature of the antigens involved in the complexes remains unknown.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 338514     DOI: 10.1002/ijc.2910200611

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  15 in total

1.  Stimulation of peripheral blood lymphocytes with autologous tumor and serum-derived fractions from patients with laryngeal carcinomas.

Authors:  P Koldovsky; U Koldovsky; J Ebbers; K H Vosteen
Journal:  Arch Otorhinolaryngol       Date:  1986

Review 2.  Immune complexes in human diseases: a review.

Authors:  A N Theofilopoulos; F J Dixon
Journal:  Am J Pathol       Date:  1980-08       Impact factor: 4.307

3.  An experimental immunocytoma model in /LOU/M/Ws1 X CFY/F1 rats: neoplastic cells as targets of the host's immune apparatus.

Authors:  E Puskás; F Uher; J Gergely; H Bazin
Journal:  Immunology       Date:  1984-07       Impact factor: 7.397

4.  [Clinical significance of circulating immune complexes in patients with metastatic breast cancer].

Authors:  G Krieger; A Kehl; I Bause; M Kneba; G A Nagel
Journal:  Klin Wochenschr       Date:  1982-12-01

5.  Correlation if circulating immune complexes and disease status in patients with leukaemia.

Authors:  R A Hubbard; M C Aggio; B B Lozzio; C J Wust
Journal:  Clin Exp Immunol       Date:  1981-01       Impact factor: 4.330

6.  Circulating immune complexes, complement and complement component levels in childhood Hodgkin's disease.

Authors:  W E Brandeis; C Tan; Y Wang; R A Good; N K Day
Journal:  Clin Exp Immunol       Date:  1980-03       Impact factor: 4.330

7.  Immune complexes with antiglobulin activity in sera of Moloney sarcoma-bearing rats.

Authors:  J R Balint
Journal:  Clin Exp Immunol       Date:  1982-04       Impact factor: 4.330

8.  [Circulating immune complexes of patients with malignant lymphomas (author's transl)].

Authors:  C P Sodomann; H Schmidt; K Havemann
Journal:  Blut       Date:  1979-06-18

9.  Circulating immune complexes of Hodgkin's disease contain an antigen that is present in Hodgkin and Reed-Sternberg cells.

Authors:  G Bepler; Q Y Zhen; K Havemann
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

10.  A comparative study of complement components in polyethylene glycol precipitated immune complexes from patients with ovarian cancer and patients with rheumatoid arthritis.

Authors:  N A Mooney; F C Hay; T A Poulton
Journal:  Clin Exp Immunol       Date:  1983-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.